Tag Archives: alzheimers

A Manhattan Project for Alzheimer’s Disease

James Greenwood STILL 5_EDIT

Earlier this month, at the Alzheimer’s Disease Summit in New York City, BIO‘s President & CEO Jim Greenwood highlighted the need for our nation to think bigger about how we approach Alzheimer’s Disease. Greenwood called for a “Manhattan Project” to rally the country around addressing this growing health challenge.  He also noted that addressing Alzheimer’s Disease is the type of issue that could bring together elected officials on both sides of the aisle. As part Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , , , ,

Unraveling the Mystery of Alzheimer’s Disease

drew-headshot

Preeminent researchers from around the world gathered recently to tackle the science behind one of medicine’s toughest problems – Alzheimer’s – and elevating the disease as a top global priority. The Global CEO Initiative on Alzheimer’s Disease (CEOi) – a coalition of corporations from the fields of biotechnology, pharmaceuticals, diagnostics, finance, and healthcare – hosted a dinner during the Alzheimer’s Association International Convention (AAIC) in Boston. The CEOi had already taken strides to achieve this Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Alzheimer’s Disease “Robs You of Everything”

Alzheimer’s Disease “Robs You of Everything”

George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Q & A with Eli Lilly’s Eric Siemers

Q+A with Eli Lillys Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Approving Drugs for Alzheimer’s Disease

Russ Katz

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory challenges. Tomorrow, we cover the first Alzheimer’s prevention trial, and on Wednesday, we will explore the societal and economic impact of this devastating disease. The therapies currently approved for Alzheimer’s disease work by treating the patients’ symptoms, improving their cognitive and overall functions. Increasingly, however, experts are intent on slowing or halting the disease process—before it has ravaged patients’ brains. In February, the U.S. Food Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,